A Follow-up Phase IIa Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 50 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs ABX 464 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Abivax
- 30 Apr 2019 According to an Abivax media release, 12-months maintenance data will be presented at annual United European Gastroenterology (UEG) week.
- 30 Apr 2019 According to an Abivax media release, 9-months maintenance data will be presented at 2019 Digestive Disease Week (DDW).
- 01 Apr 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History